Cargando…

A demonstration of cone function plasticity after gene therapy in achromatopsia

Recent advances in regenerative therapy have placed the treatment of previously incurable eye diseases within arms’ reach. Achromatopsia is a severe monogenic heritable retinal disease that disrupts cone function from birth, leaving patients with complete colour blindness, low acuity, photosensitivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Farahbakhsh, Mahtab, Anderson, Elaine J, Maimon-Mor, Roni O, Rider, Andy, Greenwood, John A, Hirji, Nashila, Zaman, Serena, Jones, Pete R, Schwarzkopf, D Samuel, Rees, Geraint, Michaelides, Michel, Dekker, Tessa M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679164/
https://www.ncbi.nlm.nih.gov/pubmed/35998912
http://dx.doi.org/10.1093/brain/awac226
_version_ 1784834133172682752
author Farahbakhsh, Mahtab
Anderson, Elaine J
Maimon-Mor, Roni O
Rider, Andy
Greenwood, John A
Hirji, Nashila
Zaman, Serena
Jones, Pete R
Schwarzkopf, D Samuel
Rees, Geraint
Michaelides, Michel
Dekker, Tessa M
author_facet Farahbakhsh, Mahtab
Anderson, Elaine J
Maimon-Mor, Roni O
Rider, Andy
Greenwood, John A
Hirji, Nashila
Zaman, Serena
Jones, Pete R
Schwarzkopf, D Samuel
Rees, Geraint
Michaelides, Michel
Dekker, Tessa M
author_sort Farahbakhsh, Mahtab
collection PubMed
description Recent advances in regenerative therapy have placed the treatment of previously incurable eye diseases within arms’ reach. Achromatopsia is a severe monogenic heritable retinal disease that disrupts cone function from birth, leaving patients with complete colour blindness, low acuity, photosensitivity and nystagmus. While successful gene-replacement therapy in non-primate models of achromatopsia has raised widespread hopes for clinical treatment, it was yet to be determined if and how these therapies can induce new cone function in the human brain. Using a novel multimodal approach, we demonstrate for the first time that gene therapy can successfully activate dormant cone-mediated pathways in children with achromatopsia (CNGA3- and CNGB3-associated, 10–15 years). To test this, we combined functional MRI population receptive field mapping and psychophysics with stimuli that selectively measure cone photoreceptor signalling. We measured cortical and visual cone function before and after gene therapy in four paediatric patients, evaluating treatment-related change against benchmark data from untreated patients (n = 9) and normal-sighted participants (n = 28). After treatment, two of the four children displayed strong evidence for novel cone-mediated signals in visual cortex, with a retinotopic pattern that was not present in untreated achromatopsia and which is highly unlikely to emerge by chance. Importantly, this change was paired with a significant improvement in psychophysical measures of cone-mediated visual function. These improvements were specific to the treated eye, and provide strong evidence for successful read-out and use of new cone-mediated information. These data show for the first time that gene replacement therapy in achromatopsia within the plastic period of development can awaken dormant cone-signalling pathways after years of deprivation. This reveals unprecedented neural plasticity in the developing human nervous system and offers great promise for emerging regenerative therapies.
format Online
Article
Text
id pubmed-9679164
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96791642022-11-22 A demonstration of cone function plasticity after gene therapy in achromatopsia Farahbakhsh, Mahtab Anderson, Elaine J Maimon-Mor, Roni O Rider, Andy Greenwood, John A Hirji, Nashila Zaman, Serena Jones, Pete R Schwarzkopf, D Samuel Rees, Geraint Michaelides, Michel Dekker, Tessa M Brain Original Article Recent advances in regenerative therapy have placed the treatment of previously incurable eye diseases within arms’ reach. Achromatopsia is a severe monogenic heritable retinal disease that disrupts cone function from birth, leaving patients with complete colour blindness, low acuity, photosensitivity and nystagmus. While successful gene-replacement therapy in non-primate models of achromatopsia has raised widespread hopes for clinical treatment, it was yet to be determined if and how these therapies can induce new cone function in the human brain. Using a novel multimodal approach, we demonstrate for the first time that gene therapy can successfully activate dormant cone-mediated pathways in children with achromatopsia (CNGA3- and CNGB3-associated, 10–15 years). To test this, we combined functional MRI population receptive field mapping and psychophysics with stimuli that selectively measure cone photoreceptor signalling. We measured cortical and visual cone function before and after gene therapy in four paediatric patients, evaluating treatment-related change against benchmark data from untreated patients (n = 9) and normal-sighted participants (n = 28). After treatment, two of the four children displayed strong evidence for novel cone-mediated signals in visual cortex, with a retinotopic pattern that was not present in untreated achromatopsia and which is highly unlikely to emerge by chance. Importantly, this change was paired with a significant improvement in psychophysical measures of cone-mediated visual function. These improvements were specific to the treated eye, and provide strong evidence for successful read-out and use of new cone-mediated information. These data show for the first time that gene replacement therapy in achromatopsia within the plastic period of development can awaken dormant cone-signalling pathways after years of deprivation. This reveals unprecedented neural plasticity in the developing human nervous system and offers great promise for emerging regenerative therapies. Oxford University Press 2022-08-24 /pmc/articles/PMC9679164/ /pubmed/35998912 http://dx.doi.org/10.1093/brain/awac226 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Farahbakhsh, Mahtab
Anderson, Elaine J
Maimon-Mor, Roni O
Rider, Andy
Greenwood, John A
Hirji, Nashila
Zaman, Serena
Jones, Pete R
Schwarzkopf, D Samuel
Rees, Geraint
Michaelides, Michel
Dekker, Tessa M
A demonstration of cone function plasticity after gene therapy in achromatopsia
title A demonstration of cone function plasticity after gene therapy in achromatopsia
title_full A demonstration of cone function plasticity after gene therapy in achromatopsia
title_fullStr A demonstration of cone function plasticity after gene therapy in achromatopsia
title_full_unstemmed A demonstration of cone function plasticity after gene therapy in achromatopsia
title_short A demonstration of cone function plasticity after gene therapy in achromatopsia
title_sort demonstration of cone function plasticity after gene therapy in achromatopsia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679164/
https://www.ncbi.nlm.nih.gov/pubmed/35998912
http://dx.doi.org/10.1093/brain/awac226
work_keys_str_mv AT farahbakhshmahtab ademonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT andersonelainej ademonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT maimonmorronio ademonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT riderandy ademonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT greenwoodjohna ademonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT hirjinashila ademonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT zamanserena ademonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT jonespeter ademonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT schwarzkopfdsamuel ademonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT reesgeraint ademonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT michaelidesmichel ademonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT dekkertessam ademonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT farahbakhshmahtab demonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT andersonelainej demonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT maimonmorronio demonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT riderandy demonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT greenwoodjohna demonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT hirjinashila demonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT zamanserena demonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT jonespeter demonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT schwarzkopfdsamuel demonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT reesgeraint demonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT michaelidesmichel demonstrationofconefunctionplasticityaftergenetherapyinachromatopsia
AT dekkertessam demonstrationofconefunctionplasticityaftergenetherapyinachromatopsia